Sumary of China rolls out new Covid cure:
- XINHUA PHOTO BEIJING: Chinese researchers are rolling out a number of remedies specific for Covid-19 treatment as the world races into the third phase of the anti-epidemic fight characterized by a combination of accessible vaccines and drugs.
- Among drug producers in China, a neutralizing monoclonal antibody combination therapy is expected to become the first in the country to get approval for market use in December.
- The combination therapy is codeveloped by Tsinghua University, the Third People’s Hospital of Shenzhen and Brii Biosciences, a company that has dual headquarters in China and the United States.
- The goal of our research is to pick out the strongest ones that can be used as antibody drugs to treat infected patients,” Zhang Linqi, a professor at the School of Medicine at Tsinghua University, was quoted as saying by Science and Technology Daily on Monday.
- Tao Lina, an expert on immunology, told the Global Times that the theory of neutralizing antibody-based therapies is to use the antibody in the medicines to neutralize the virus.
- } Brii Biosciences announced in late August that its SARS-CoV-2 therapy BRII-196/BRII-198 demonstrated a statistically significant reduction of 78 percent in the hospitalization and death in phase 3 clinical trials conducted in the United States, Brazil, South Africa, Mexico, Argentina and the Philippines.
- It is most likely for the therapy to be authorized for emergency use in the United States, the Science and Technology Daily report said, citing a source from Brii.
- The therapy has also proven effective against major coronavirus variants including the Delta, Lambda and MU variants, the Beijing Daily reported.